TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05641324

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.
“The study was ended due to a lack of recruitment”

The sponsor’s own words in the registry.

Life of this trial

202220232024Registered2022-11-29Started2023-02-10Stopped2023-07-12

Vital statistics

Status
Terminated
Phase
Phase 1
Sponsor
Anaveon AG
Sponsor type
Industry
Conditions
Multiple Myeloma; Relapsed Cancer; Refractory Multiple Myeloma; Adult Disease; Hematologic Diseases
Interventions
ANV419; Lenalidomide with low-dose dexamethasone; Daratumumab
Participants
4
Sites
11
Countries
Denmark, France, Germany, Spain, Switzerland

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.